Analysts count on revenue increase Celgene

Tomorrow the American Celgene will publish its past quarters figures. Over the current book year the total revenue will be 15,23 billion USD (consensus estimates). This is hugely more than 2017's revenue of 13 billion USD.

Historical revenues and results Celgene plus estimates 2018

financial analysis

The analysts expect for 2018 a net profit of 6,5 billion USD. For this year most of the analysts expect a profit per share of 8,8 USD. With this the price/earnings-ratio is 9,8.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0,5 percent.

Newest target prices around 99 USD

The most recent recommendations for the biotech company are from Morgan Stanley, JP Morgan and Barclays.

Based on the current number of outstanding shares Celgene's market capitalization is 67,17 billion USD. The Celgene stock was the past 12 months quite volatile. Since last January the stock is 16 percent lower. This year the stock price moved between 59 and 107 dollar. Since 2008 the stock price is almost 251 percent higher.

At 23.00 the stock trades 0,31 percent lower at 86,27 USD.

Historical stock prices Celgene from 2007 till 2018

financial analysis <a href='/stock/444-celgene'>Celgene</a>

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.